|
Chronic Lymphocytic Leukemia
|
0.300 |
Biomarker
|
disease |
CTD_human |
Scan of 977 nonsynonymous SNPs in CLL4 trial patients for the identification of genetic variants influencing prognosis.
|
18006695 |
2008 |
|
Alcohol consumption
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Genome-wide association study identifies two loci strongly affecting transferrin glycosylation.
|
21665994 |
2011 |
|
Malignant Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
Topoisomerase IIβ-binding protein 1 (TOPBP1) participates in DNA replication and DNA damage response; however, its role in DNA repair and relevance for human cancer remain unclear.
|
26811421 |
2016 |
|
Malignant Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
The expression levels of TopBP1 and Claspin were increased in the cancer cells that survived radiation therapy.
|
25216549 |
2014 |
|
Malignant Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
The level of TopBP1 mRNA appeared to be lower in poorly differentiated (III grade) hereditary breast cancer in comparison with moderately (II grade) and well-differentiated cancer (I grade) (p < 0.05 and p < 0.001 respectively).
|
22544570 |
2012 |
|
Malignant Neoplasms
|
0.080 |
GeneticVariation
|
group |
BEFREE |
We found somatic frameshit mutations of the KNTC1 (6.7% GC, 12.1% CRC), ZC3H13 (3.3% GC, 15.2% CRC), CENPH (6.7% GC), TOPBP1 (3.0% CRC), NDCO80 (3.0% CRC), RIF1 (6.7% GC), and NBS1 (3.3% GC, 3.0% CRC) genes in the cancers with MSI-H. Mutations were detected in MSI-H, but not in MSI-L or MSS samples.
|
21388066 |
2011 |
|
Malignant Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
Although the roles of TopBP1 have been studied mostly in cancer cell lines, its physiological function remains unclear in mice and untransformed cells.
|
21149450 |
2011 |
|
Malignant Neoplasms
|
0.080 |
GeneticVariation
|
group |
BEFREE |
Thus, TopBP1 mediates mutant p53 gain of function in cancer.
|
21930790 |
2011 |
|
Malignant Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
Thus, a physiological level of TopBP1 is essential for normal G(1)/S transition, but a pathological level of TopBP1 in cancer may perturb p53 function and contribute to an aggressive tumor behavior.
|
19289498 |
2009 |
|
Malignant Neoplasms
|
0.080 |
GeneticVariation
|
group |
BEFREE |
Over 50% of the genes identified in this screen have putative human homologs, including CHEK2, ERCC4, and TOPBP1, which are already associated with inherited cancer susceptibility.
|
18245329 |
2008 |
|
Primary malignant neoplasm
|
0.070 |
Biomarker
|
group |
BEFREE |
Topoisomerase IIβ-binding protein 1 (TOPBP1) participates in DNA replication and DNA damage response; however, its role in DNA repair and relevance for human cancer remain unclear.
|
26811421 |
2016 |
|
Primary malignant neoplasm
|
0.070 |
AlteredExpression
|
group |
BEFREE |
The expression levels of TopBP1 and Claspin were increased in the cancer cells that survived radiation therapy.
|
25216549 |
2014 |
|
Primary malignant neoplasm
|
0.070 |
AlteredExpression
|
group |
BEFREE |
The level of TopBP1 mRNA appeared to be lower in poorly differentiated (III grade) hereditary breast cancer in comparison with moderately (II grade) and well-differentiated cancer (I grade) (p < 0.05 and p < 0.001 respectively).
|
22544570 |
2012 |
|
Primary malignant neoplasm
|
0.070 |
Biomarker
|
group |
BEFREE |
Although the roles of TopBP1 have been studied mostly in cancer cell lines, its physiological function remains unclear in mice and untransformed cells.
|
21149450 |
2011 |
|
Primary malignant neoplasm
|
0.070 |
GeneticVariation
|
group |
BEFREE |
Thus, TopBP1 mediates mutant p53 gain of function in cancer.
|
21930790 |
2011 |
|
Primary malignant neoplasm
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Thus, a physiological level of TopBP1 is essential for normal G(1)/S transition, but a pathological level of TopBP1 in cancer may perturb p53 function and contribute to an aggressive tumor behavior.
|
19289498 |
2009 |
|
Primary malignant neoplasm
|
0.070 |
GeneticVariation
|
group |
BEFREE |
Over 50% of the genes identified in this screen have putative human homologs, including CHEK2, ERCC4, and TOPBP1, which are already associated with inherited cancer susceptibility.
|
18245329 |
2008 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
We determined that TopBP1 levels are increased in cervical intraepithelial neoplasias as well as cervical carcinomas, consistent with studies in HPV-positive cell lines.
|
30631149 |
2019 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
CR-LAAO altered the tumor cell expression of DNA repair genes, with two downregulated (XRCC4 and TOPBP1) and three upregulated (ERCC6, RAD52 and CDKN1) genes.
|
29738841 |
2018 |
|
Bloom Syndrome
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
(2017) show that a single BRCT domain in TopBP1 binds tightly and specifically to phosphorylated Bloom syndrome helicase (BLM).
|
28978405 |
2017 |
|
Bloom Syndrome
|
0.040 |
Biomarker
|
disease |
BEFREE |
It was proposed that TopBP1 BRCT5 interacts with Bloom syndrome helicase (BLM) to regulate genome stability through either phospho-Ser304 or phospho-Ser338 of BLM.
|
28919440 |
2017 |
|
Neoplasms
|
0.040 |
GeneticVariation
|
group |
BEFREE |
The presence of risk allele at rs115160714 TopBP1 determined a higher incidence of nodal metastases (OR = 7.98, 95 % CI: 3.94-16.00, p = 0.001) and higher tumor grade (OR = 6.48, 95 % CI: 0.86-48.01, p = 0.03).
|
26503213 |
2016 |
|
Bloom Syndrome
|
0.040 |
Biomarker
|
disease |
BEFREE |
The Bloom syndrome helicase BLM and topoisomerase-IIβ-binding protein 1 (TopBP1) are key regulators of genome stability.
|
25794620 |
2015 |
|
Bloom Syndrome
|
0.040 |
Biomarker
|
disease |
BEFREE |
In this study, we report a specific interaction between TopBP1 and Bloom syndrome helicase (BLM) that is phosphorylation and cell-cycle dependent.
|
24239288 |
2013 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Thus, a physiological level of TopBP1 is essential for normal G(1)/S transition, but a pathological level of TopBP1 in cancer may perturb p53 function and contribute to an aggressive tumor behavior.
|
19289498 |
2009 |